Affiliation:
1. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) Health Research Institute of Santiago de Compostela (IDIS) Department of Pharmacology Pharmaceutics and Pharmaceutical Technology School of Pharmacy University of Santiago de Compostela Santiago de Compostela 15782 Spain
Abstract
AbstractThe success of personalized medicine in oncology relies on using highly effective and precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal antibodies (mAbs). Unfortunately, the clinical exploitation of these biological drugs has encountered obstacles in overcoming intricate biological barriers. Drug delivery technologies represent a plausible strategy to overcome such barriers, ultimately facilitating the access to intracellular domains. Here, an overview of the current landscape on how nanotechnology has dealt with protein corona phenomena as a first and determinant biological barrier is presented. This continues with the analysis of strategies facilitating access to the tumor, along with conceivable methods for enhanced tumor penetration. As a final step, the cellular barriers that nanocarriers must confront in order for their biological cargo to reach their target are deeply analyzed. This review concludes with a critical analysis and future perspectives of the translational advances in personalized oncological nanomedicine.
Funder
Ministerio de Universidades
Ministerio de Ciencia e Innovación
Instituto de Salud Carlos III
Ministerio de Ciencia, Innovación y Universidades
Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia
Xunta de Galicia
Subject
Mechanical Engineering,Mechanics of Materials,General Materials Science